AIMS Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa-carbidopa delivery through intrajejunal infusion. This study characterized the population pharmacokinetics of levodopa following a 16 h jejunal infusion of LCIG or frequent oral administration of levodopa-carbidopa tablets (LC-oral) in subjects with advanced Parkinson's disease (PD). METHODS A non-linear mixed-effects ...

OBJECTIVE To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson's disease with both fluctuating and non-fluctuating response to treatment. METHODS A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating p...

Abstract: Purpose: The present work evaluated the neuroprotective potential of embelin either alone and in combination with Levodopa rotenone induced PD (Parkinson’s disease) model mice. Methods: Swiss albino male adult mice were randomly divided into 7 groups. Group-1 (Control) received 2mL/kg olive oil by oral route (p.o.), Groups from 2 to 2.5mg/kg intraperitoneal (i.p.), levodopa was admini...

BACKGROUND Dopa responsive dystonia is characterized by progressive disabling dystonia, diurnal variation and a dramatic response to Levodopa. CASE CHARACTERISTICS Two siblings presented with regression of motor milestones and hypertonia in lower limbs. History of diurnal variation was present in elder sibling. OUTCOME Both responded dramatically to Levodopa. The genomic DNA analysis of eld...

In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with different pharmacological profile a...

There were few cases of thrombocytopenia associated with levodopa. Herein, we report a patient with Parkinson's disease, who suffered thrombocytopenia related to long-term use of levodopa.

A portable test to rapidly determine levels of levodopa, the drug used treat Parkinson's disease, can improve clinical management disease. In this study, screen-printed electrodes (SPEs) were modified with polymers facilitate electrochemical detection levodopa. Cyclic voltammetry was deposit a thin layer polyaniline on electrode surface. Scanning electron microscopy revealed high surface covera...

purpose: to evaluate the effect of levodopa-carbidopa on improvement of visual acuity, color vision, and visual field in patients with nonarteritic anterior ischemic optic neuropathy (naion) with onset less than 6 wks. methods: in this double-blind randomized controlled trial, 13 patients were treated with levodopa-carbidopa and 12 patients were treated with placebo for 3 weeks. after 6 months,...

Three decades after its introduction, levodopa remains the gold standard for the treatment of Parkinson’s disease (PD). Levodopa is the most potent symptomatic antiparkinsonian agent, and it is associated with an increase in quality of life and longevity for patients with PD. Dopamine agonists are increasingly being used, not only as an adjunct to levodopa, but as early therapy aimed at reducin...

5-Hydroxytryptamine 1a (5-HT(1a)) receptor agonists, such as sarizotan and tandospirone, are reported to reduce levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques and in Parkinson's disease without worsening motor disability. However, these compounds are not specific for 5-HT(1a) receptors and also possess dopamine antagonist actions. We now repo...